PSMD2 and lung adenocarcinoma: As shown in Figure 3B, the disease-specific survival of lung adenocarcinoma patients with higher PSMD2 expression was also significantly shorter than those with lower PSMD2 expression (59.9 months vs. not available, p = 0.004).